Research programme: protein degrader therapeutics - Cullgen
Latest Information Update: 17 Sep 2024
At a glance
- Originator Cullgen
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Lung cancer; Lymphoma; Prostate cancer
Most Recent Events
- 07 Aug 2024 Early research in Lung cancer in USA (unspecified route) prior to August 2024 (Cullgen pipeline, August 2024)
- 07 Aug 2024 Early research in Lymphoma in USA (unspecified route) prior to August 2024 (Cullgen pipeline, August 2024)
- 07 Aug 2024 Early research in Prostate cancer in USA (unspecified route) prior to August 2024 (Cullgen pipeline, August 2024)